Premium
Cisplatin induces differentiation of breast cancer cells
Author(s) -
Prabhakaran Praseetha,
Hassiotou Foteini,
Filgueira Luis
Publication year - 2012
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.26.1_supplement.914.2
Subject(s) - cisplatin , cancer research , cancer stem cell , breast cancer , stem cell , stem cell marker , cell , cellular differentiation , cell culture , cd44 , biology , oncology , chemotherapy , cancer , medicine , microbiology and biotechnology , genetics , gene
Breast tumours are heterogeneous, including cells with cancer stem cell properties and more differentiated tumour cells. As breast cancer stem cells are often resistant to chemotherapy, recent efforts have been focusing on treatments that may shift them towards a more differentiated phenotype, making them more susceptible to treatment. Here, we examined whether t cisplatin induces cell differentiation in four breast cancer cell lines that represent different types of breast tumours (BT549, MDA‐MB‐468, MDA‐MB‐231, MCF7). Cisplatin treatment of 20 μM reduced cell viability from 100% to 50–80%, depending on the cell line. Flow cytometric quantification showed that treatment with cisplatin induced a 18–65% decrease of stem cell marker expression (CD49f, SSEA4) and a 4–97% increase in expression of differentiation markers (CK18, Tubulin). It is concluded that in addition to its effects on cell survival, cisplatin shifts breast cancer cell lines towards a more differentiated phenotype. Research Support: Malaysian Ministry of Higher Education Postgraduate Scholarship